Submit a comment
Citation Information: J Clin Invest. 1974;54(3):646-653. https://doi.org/10.1172/JCI107802.
Abstract
Kinetics of 5α-androstane-3α, 17β-diol (3α-diol) were studied in man. Clearance rates were determined by both the constant infusion and single injection techniques. Production rates were calculated as the product of clearance rate data and plasma values in the a.m. obtained by a radioimmunoassay specific for 3α-diol. Mean metabolic clearance rates were 1,776±492 (SD) liters/day in males and 1,297±219 (SD) liters/day in females. Metabolic clearance rates by single injection were similar. Calculated production rates are 208±26 (SD) μg/day in males and 35±11 μg/day in females, which are significantly different. Hepatic extraction of 3α-diol determined by hepatic vein catheterization during constant infusion was 76% which was greater than expected from information on in vitro binding in plasma. The kinetic data is of interest since 3α-diol has a calculated inner pool (V1) volume of 12-14 liters, similar to 17β-hydroxyandrost-4-en-3-one (testosterone) and 5α-androstan-17β-ol-3-one (dihydrotestosterone), but the calculated outer pool (V2) of 33.5 liters is very large as are the metabolic rate and transfer constant. In contrast to testosterone and dihydrotestosterone, 3α-diol, although bound to sex hormone binding globulin, has a high metabolic clearance of which a large fraction represents extrahepatic (splanchnic) metabolism. A production rate of 3α-diol similar to dihydrotestosterone together with rather unique kinetic characteristics encourages further investigation of the biological role of this potent androgen.
Authors
T. Kinouchi, R. Horton
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)